This year’s Annual Meeting was held live in Seattle, USA, from 2-7 April, with delegates meeting in person for presentations on the latest clinical and scientific data including research on anti-CGRP therapies.
Significant reductions in opioid use and in medication overuse headache (MOH) have been reported from an analysis of prescription claims data from a longitudinal commercial pharmacy database in the months following rimegepant initiation for migraine. Eighteen month follow up data for the opioid use analysis showed a 16.06% reduction in total opioid prescriptions filled in …
Read more »Atogepant appears to partially prevent activation of both Aδ- and C-fibre meningeal nociceptors, according to results of a mechanistic study using single-unit recordings of activity in trigeminal ganglion neurons innervating the dura in response to cortical spreading depression (CSD). Atogepant did not fully prevent activation of nociceptors (incidence of response to CSD in Aδ-fibres [vehicle 73%, …
Read more »When a patient with migraine starts ubrogepant whilst their pain is mild, they are more likely to be free of pain and other symptoms after two hours than if they delay until their pain is moderate or severe. This is the conclusion of a post-hoc, within-person analysis of efficacy data from patients who treated at …
Read more »Post-hoc analyses of data from studies of atogepant for migraine prevention have shown treatment-related, dose-dependent reductions in body weight compared with placebo and standard care. In the ADVANCE trial, least squared (LS) mean percentage change in body weight from baseline to 12 weeks was +0.37 with placebo versus +0.14 (p=0.4138), -0.61 (p=0.0005), and -1.27 (p<0.0001) …
Read more »Patients with chronic migraine (CM) who reduce attacks to four or fewer monthly headache days achieve superior outcomes, with least need for acute medication. This is the conclusion of a post hoc analysis of data from the PROMISE-2 trial evaluating eptinezumab for CM prevention. The analysis showed that, of patient-months with ≤4 MHDs, 67.6% (561/830) …
Read more »Fremanezumab treatment resulted in clinically meaningful reductions in monthly migraine days (MMD) and significant improvements in disability outcomes in patients with prior onabotulinumtoxinA treatment failure. These were the findings from pooled data from the Phase 3 HALO EM, HALO CM, and FOCUS trials in which patients were randomized 1:1:1 to quarterly or monthly fremanezumab or …
Read more »Safety and efficacy data from the DRAGON study of erenumab 70 mg in adult patients with chronic migraine in China and other Asian countries are consistent with previous pivotal studies. In the 12-week Phase 3 study of 557 patients with chronic migraine, those in the erenumab 70 mg group had a significantly greater reduction in …
Read more »Intranasal zavegepant in doses up to 40mg per day has demonstrated good safety and tolerability in healthy adults, with doses ≥10 mg producing exposures predictive of efficacy in adults with migraine.1 These results from two Phase 1, placebo-controlled, randomised, double-blind, sequential zavegepant studies provide supportive data following previous reports of Phase 3 data demonstrating significantly …
Read more »High completion rates and sustained safety and tolerability were reported from an open access programme for galcanezumab in patients who completed the 3-month double-blind and 9-month open-label phases of the Phase III REGAIN trial (NCT02614261). Patients entered the three year continuous access programme for galcanezumab approximately five to 13 months after their last study dose. …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
